Phathom Pharmaceuticals announces initiation of pivotal phase 3 clinical trial for vonoprazan in erosive esophagitis

This article was originally published here

PHALCON-EE is a randomized, double-blind, two-phase, multicenter Phase 3 trial that is planned to enroll approximately 1,000 patients with EE in the U.S. and Europe. The first phase

The post Phathom Pharmaceuticals announces initiation of pivotal phase 3 clinical trial for vonoprazan in erosive esophagitis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply